Please login to the form below

Not currently logged in
Email:
Password:

Orexigen

This page shows the latest Orexigen news and features for those working in and with pharma, biotech and healthcare.

Takeda files block on generic diet pill launch

Takeda files block on generic diet pill launch

Orexigen and its partner Takeda have taken Actavis to court to block a generic version of the firms' diet pill Contrave. ... The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment

Latest news

  • Saxenda debuts in US with $1,000-a-month price tag Saxenda debuts in US with $1,000-a-month price tag

    The Danish drugmaker has launched Saxenda in the US at a price of just over $1, 000 per month, significantly more than other recently-launched obesity drugs such as

  • Positive data in Saxenda diabetes prevention study Positive data in Saxenda diabetes prevention study

    the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion). ... None of these has made significant headway since their US launches, and of the three only

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world ... markets. The picture in Europe is different, however,

  • Orexigen’s obesity pill Mysimba set for European approval Orexigen’s obesity pill Mysimba set for European approval

    The drug efficacy and safety arm of the European Medicines Agency has recommended Orexigen Therapeutics' new anti-obesity drug Mysimba for certain patients to help them lose weight. ... The drug is a combination of the antidepressant bupropion and

  • Takeda's obesity drug Contrave launches in US Takeda's obesity drug Contrave launches in US

    Takeda has launched its chronic weight management drug Contrave onto the US market, four years after first licensing the treatment from originator Orexigen Therapeutics. ... Orexigen believes it will benefit from the market being developed by its

More from news
Approximately 4 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Mark Booth joins Probiodrug Mark Booth joins Probiodrug

    Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics